Papillary thyroid cancer risk was higher in children exposed to increased fine particulate matter and outdoor artificial light at night.

Molecular alteration patterns were a better predictor of aggressive tumor behavior than tumor size in papillary thyroid carcinoma.

Thyroid disorders impact over 42 million Indians, affecting energy, mood, and metabolism. Early diagnosis, proper diet, and routine monitoring are vital for effective management and prevention., Healt ...

It is made from the dried and powdered thyroid glands of pigs and contains a mix of thyroid hormones, including thyroxine (T4) and triiodothyronine (T3). The hormones in Armour Thyroid help regulate ...

ImmunityBio, Inc, a leading immunotherapy company, announced that it has completed multiple submissions to the US FDA including an sBLA for BCG-unresponsive NMIBC in papillary disease and an EAP for ...

"Elraglusib with chemotherapy and immune priming represents a novel sequential therapy approach to treat advanced salivary cancers. We were encouraged by the response rate among the non-Adenoid ...

Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and disease-free ...

Thyroid cancers are tumours of the thyroid gland, and originate from follicular or parafollicular cells. These are often caused by radiation exposure, and can present as a nodule in the anterior ...

for the indication of papillary disease. In Q2, the company submitted to the U.S. Food and Drug Administration (FDA) an Expanded Access Protocol (EAP) for ANKTIVA for the treatment of lymphopenia ...

Multiple predictors were linked to biochemical or structural evidence of disease 1 year after papillary thyroid microcarcinoma diagnosis. Risk stratification should be used to guide management of ...

ImmunityBio seeks FDA approval for Anktiva plus BCG in BCG-unresponsive NMIBC papillary indication, supported by QUILT-3.032 trial data. The QUILT-3.032 trial showed a 55.4% disease-free survival at ...

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...